Alexion Pharmaceuticals I... (ALXN)
NASDAQ: ALXN
· Real-Time Price · USD
182.50
0.00 (0.00%)
At close: Apr 24, 2025, 3:47 PM
Alexion Pharmaceuticals Revenue Breakdown
| Period Ending | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|
| Product and Service, Other Revenue | 800K | 1.1M | 1.1M |
| Product and Service, Other Revenue Growth | -27.27% | 0.00% | n/a |
| Product Revenue | 6.07B | n/a | n/a |
| Product Revenue Growth | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asia Pacific Revenue | 255.3M | 49.9M | 27.9M | 18.6M | 318M | 276.35M | 244.06M | 203.54M | 161.48M | 115.38M |
| Asia Pacific Revenue Growth | +411.62% | +78.85% | +50.00% | -94.15% | +15.07% | +13.23% | +19.91% | +26.05% | +39.96% | n/a |
| Europe Revenue | 170.4M | 52.2M | 61.7M | 35.6M | 961M | 840.47M | 836.13M | 514.99M | 418.32M | 340.81M |
| Europe Revenue Growth | +226.44% | -15.40% | +73.31% | -96.30% | +14.34% | +0.52% | +62.36% | +23.11% | +22.74% | n/a |
| Non-Us, Excluding Europe And Asia Pacific Revenue | 5M | n/a | 11.2M | 5.5M | 1.26B | 951.31M | 730.09M | 561.4M | 400.48M | 263.39M |
| Non-Us, Excluding Europe And Asia Pacific Revenue Growth | n/a | -100.00% | +103.64% | -99.56% | +32.13% | +30.30% | +30.05% | +40.18% | +52.05% | n/a |
| United States Revenue | 646M | 236.8M | 374.3M | 280.1M | n/a | n/a | n/a | n/a | n/a | n/a |
| United States Revenue Growth | +172.80% | -36.74% | +33.63% | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 342.9M | 444.4M | 334.2M | 301.4M | 319.9M | 381M | 299.3M | 299.3M | 281.5M | 318.7M | 258.7M | 277.3M | 257.1M | 296.4M | 271M | 265M | 262M | 259.51M | 230.13M | 231.8M | 232.56M | 241.58M | 212.52M | 221.38M | 187.12M |
| Selling, General, and Administrative Revenue Growth | -22.84% | +32.97% | +10.88% | -5.78% | -16.04% | +27.30% | 0.00% | +6.32% | -11.67% | +23.19% | -6.71% | +7.86% | -13.26% | +9.37% | +2.26% | +1.15% | +0.96% | +12.77% | -0.72% | -0.33% | -3.73% | +13.67% | -4.00% | +18.31% | n/a |
| Research and Development Revenue | 289.1M | 295M | 285.9M | 221.1M | 200.9M | 269.6M | 232.9M | 187.6M | 195.9M | 205.6M | 174.8M | 173.4M | 176.6M | 265.4M | 195M | 199M | 219M | 205.71M | 195.69M | 179.31M | 176.29M | 191.03M | 165.66M | 131.69M | 221.08M |
| Research and Development Revenue Growth | -2.00% | +3.18% | +29.31% | +10.05% | -25.48% | +15.76% | +24.15% | -4.24% | -4.72% | +17.62% | +0.81% | -1.81% | -33.46% | +36.10% | -2.01% | -9.13% | +6.46% | +5.12% | +9.13% | +1.71% | -7.72% | +15.31% | +25.80% | -40.43% | n/a |